Gastroenterology · Proton Pump InhibitorRegulatory Approvalcommercialnear-term

FDA Grants Approval for Pantoprazole Sodium ANDA219973

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/5/2026, 6:06:23 AM

Assessment confidence: 66% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of a generic version of Pantoprazole Sodium by Shuangcheng introduces a new competitor in the proton pump inhibitor market, which could disrupt pricing and market share dynamics. Pharma strategy teams must evaluate the implications for their portfolios and competitive positioning. Regulatory context from FDA (FDA AP — PANTOPRAZOLE SODIUM (ORIG)) supports the near-term read. Assessment grounded in 17 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market dynamics and consider strategies to maintain competitive positioning. The strongest clinical anchor is Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer (ClinicalTrials.gov), moderate corpus alignment. In Gastroenterology · Proton Pump Inhibitor, 8 regulatory and 1 competitive items passed relevance filtering for Shuangcheng.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for TZIELD (Teplizumab-MZWV) Supplement (Humanexa Signals) — moderate corpus alignment. This approval introduces a new generic competitor in the proton pump inhibitor market, potentially impacting pricing and market share of existing branded products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PANTOPRAZOLE SODIUM (ORIG) (FDA). Entity match (shuangcheng); Regulatory pathway relevance (nda). The approval signifies compliance with FDA standards, but does not indicate any changes to existing regulatory frameworks for other products.

Key Risks

Clinical risk from ClinicalTrials.gov (Brisk Walking and Baduanjin Improve Inhibitory Function in Older Adults With Cognitive Impairment) could weigh on Shuangcheng through efficacy or safety read-through uncertainty if follow-through weakens.
Clinical risk from ClinicalTrials.gov (DAPAgliflozin for Renal Protection in Heart Transplant Recipients) could weigh on Shuangcheng through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The entry of a generic competitor may lead to price reductions and increased competition, potentially affecting revenue and market share for existing branded products in the proton pump inhibitor category.
Upside for Shuangcheng may improve if Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer (ClinicalTrials.gov) delivers favorable follow-through.
CDK4/6 inhibitors (CDK4/6i) represent the standard treatment for HR+/HER2- ABC. The study assessed the efficacy and safety profiles of CDK4/6i from first-line (1 L) to third-line (3 L) in patients with HR+/HER2- ABC from high-altitude versus low-altitude regions.
Portfolio teams should assess the impact of this approval on market dynamics and consider strategies to maintain competitive positioning.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and pricing strategies of Shuangcheng's product, as well as responses from existing competitors.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PANTOPRAZOLE SODIUM (ORIG)
FDAhigh relevance
Entity match (shuangcheng); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PANTOPRAZOLE SODIUM (SUPPL)
FDAhigh relevance
Entity match (pantoprazole sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FOSTAMATINIB DISODIUM (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Brisk Walking and Baduanjin Improve Inhibitory Function in Older Adults With Cognitive Impairment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With Bruton's Tyrosine Kinase Inhibitor and B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
DAPAgliflozin for Renal Protection in Heart Transplant Recipients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for TZIELD (Teplizumab-MZWV) Supplement
Humanexa Signalsmedium relevance
Moderate corpus alignment

Self-perceived learning outcomes of academic detailing discussing rational therapy with proton pump inhibitors among general practitioners in Norway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Systematic identification of bacterial neuraminidase inhibitors from Psoralea corylifolia using ultrafiltration-UPLC-Q-Orbitrap-MS and molecular dynamics.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Shuangcheng
Pantoprazole Sodium

Commercial impact

medium

The entry of a generic competitor may lead to price reductions and increased competition, potentially affecting revenue and market share for existing branded products in the proton pump inhibitor category.

Regulatory impact

low

The approval signifies compliance with FDA standards, but does not indicate any changes to existing regulatory frameworks for other products.

What to watch

Monitor market entry timelines and pricing strategies of Shuangcheng's product, as well as responses from existing competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.